Source: Eur Respir J 2007; 29: 432-434
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hoeper M. M.. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value. Eur Respir J 2007; 29: 432-434

Member's Comments

No comment yet.

Related content which might interest you: Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001 End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 How to increase the value of randomised trials in COPD research Source: Eur Respir J 2009; 34: 552 Year: 2009 Effectiveness of the tromboembolic venous disease treatments estimated through clinical trials vs. observational studies Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 An international survey of current pulmonary arterial hypertension (PAH) management Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Hispanic patients with pulmonary arterial hypertension: Preliminary results from a contemporary national registry Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Positive pressure in chronic heart failure - any role? The evidence from clinical trials Source: Annual Congress 2008 - Noninvasive positive pressure in heart failure - where are we now with two large multicentre studies showing no apparent benefit? Year: 2008 Clinical trials in pulmonary arterial hypertension: what they tell us Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Clinical trials in pulmonary arterial hypertension: what do they tell us Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017